Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced (“HTE") Subjects Jan 10, 2022 8:00am EST
Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose Jan 05, 2022 9:26am EST
CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population Dec 21, 2021 8:56am EST
NASH Phase 2 Trial Open-Label Portion Demonstrates Average 80 msec cT1 Reduction in 50% of Patients and Reduction of Nearly 50 msec in 80% of Patients Dec 13, 2021 8:00am EST
CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population Dec 09, 2021 8:56am EST
CytoDyn Files for Expanded Access Use of Leronlimab for Multi-Drug Resistance HIV Patients Dec 09, 2021 8:26am EST
